Peripheral blood and bone marrow changes after treatment with atra and G-CSF in AML, APL and blast crisis following Vaquez's disease

Haematologica

Volumn 81, Issue 3, 1996, Pages 261-264

  Notario, Antonia ^a,b   Rolandi, Maria Laura ^a   Mazzucchelli, Iolanda ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Institute of Medical Therapy   (Italy)

Author keywords

Acute myeloid leukemia; Acute promyelocytic leukemia; ATRA; G CSF; Vaquez's disease

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; PANCYTOPENIA; POLYCYTHEMIA VERA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLAST CRISIS; BLOOD CELLS; BONE MARROW; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; POLYCYTHEMIA VERA; TRETINOIN;

EID: 0030322140     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Diverio D, Riccioni R, Mandelli F, Lo Coco F. The PML/RARα fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia. Haematologica 1995; 80:155-60.
2. Kurzrock R, Estey E, Talpaz M. All transretinoic acid: Tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 1993; 11:1489-95.
3. Miller WH, Levine K, De Blasio A, et al. Detection of minimal residual disease in acute promyelocytic leukemia by reverse transcription polymerase chain reaction assay for PML/RAR-α fusion mRNA. Blood 1994; 82:1689-94.
4. Borrow J, Goddard AD, Gibbson B, et al. Diagnosis of acute promyelocytic leukemia by RT-PCR: detection of PML-RARα and RARα-PML fusion transcripts. Br J Haematol 1992; 82:529-40.
5. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precurosr cells. Cell 1993; 11:1489-93.
6. Wiernik PH, Dutcher JP, Paietta E, et al. Treatment of promyelocytic blastic crisis of chronic myelogenous leukemia with all-transretinoic acid. Leukemia 1991; 5:504-9.
7. Muindi JRF, Frankel SR, Huselton C, et al. Clinical pharmacology of all-transretinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992; 52: 2138-42.
8. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10:839-64.
9. Coutts J, Plumb A, Brown R, et al. Expression of topoisomerase II alpha in an adenocarcinoma cell line carrying amplified topoisomerase II α and retinoid acid receptor alpha genes. Br Med J 1993; 68:793-800.
10. Notario A, Mazzucchelli I, Fossati G, et al. Growth and differentiating factors on cultured cells from peripheral CFU of normal and leukemic subjects. Acta Oncol 1996; in press.
11. Bedi A, Griffin CA, Barber JP, et al. Growth factor-mediated differentiation of chronic myeloid leukemia. Cancer Res 1994; 54:5535-8.